Managed Healthcare Executive (10/7, Cox) reports, “All-cause mortality rates are more than three-fold higher in patients with schizophrenia, including a three-fold increased risk of death from Type 2 diabetes and a two-fold increased risk of death from cardiovascular disease,” but research “published in JAMA Psychiatry provides strong evidence that semaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1 RA) that is given once a week, may help control metabolic risk factors in patients who are at high risk.” Investigators “evaluated semaglutide in adults with schizophrenia and prediabetes who” had overweight or obesity “and who were prescribed second-generation antipsychotics.” The investigators “found that semaglutide significantly improved both glycemic control and body weight.” Meanwhile, “from a quality-of-life standpoint, semaglutide substantially enhanced physical quality of life.”
Related Links:
— “Semaglutide as a Dual Solution for Psychiatric and Metabolic Care,” Andrew Cox, Managed Healthcare Executive, October 7, 2025